Clinical Trials Sponsored by Beijing JD Biotech Co. LTD.

Total 1307 results

Peking University People's Hospital
Beijing JD Biotech Co. LTD.

Recruiting

Off-the-shelf CD123 CAR-NK for R/R AML

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Affiliated Hospital to Academy of Military Medical...
Beijing JD Biotech Co. LTD.

Recruiting

CAR-NK Targeted CD19 for r/r B-cell Malignancies

Adult Relapsed/Refractory B-cell Hematologic Malignancies

China
Affiliated Hospital to Academy of Military Medical...
Beijing JD Biotech Co. LTD.

Recruiting

Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia Refractory | Acute Myeloid Leukemia Recurrent

China
Beijing Dongfang Biotech Co., Ltd.

Not yet recruiting

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin

Type2 Diabetes Mellitus

China
Beijing Dongfang Biotech Co., Ltd.

Not yet recruiting

A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients

Type 2 Diabetes Mellitus

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Clinical Study of MIL62 in Primary Membranous Nephropathy

Primary Membranous Nephropathy

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL

Non-Hodgkin's Lymphoma

China
Beijing Baylx Biotech Co., Ltd.

Recruiting

Safety and Efficacy Study of Human Umbilical Cord-Derived Mesenchymal Stem Cells(BC-U001) for Rheumatoid Arthritis

Rheumatoid Arthritis

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Clinical Study of MIL93 in Solid Tumors.

Advanced Malignancies

China
Beijing Northland Biotech. Co., Ltd.

Recruiting

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1)

Ischemia | Peripheral Vascular Disease | Arterial Occlusive Disease | Ulcers

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Follicular Lymphoma and Marginal Zone Lymphoma

China
Beijing Northland Biotech. Co., Ltd.

Completed

Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction

Acute Myocardial Infarction

China
Beijing Northland Biotech. Co., Ltd.

Recruiting

Angiogenesis and Blood Perfusion Effect of HGF Gene Therapy in PAD Patients

Peripheral Artery Disease

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Clinical Study of MIL62 in Primary Membranous Nephropathy

Primary Membranous Nephropathy

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica Spectrum Disorder

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

Treatment of Advanced and Metastatic Solid Tumors With MIL97

Advanced or Metastatic Solid Tumor

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

Follicular Lymphoma and Marginal Zone Lymphoma

China
Beijing Northland Biotech. Co., Ltd.

Recruiting

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-2)

Ischemia | Peripheral Vascular Disease | Arterial Occlusive Disease | Ulcers

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor

HER2-positive Recurrent or Metastatic Malignant Solid Tumor

China
Beijing Dongfang Biotech Co., Ltd.

Active, not recruiting

Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects

Diabetes Mellitus, Type 2 | Overweight

China
Beijing Northland Biotech. Co., Ltd.

Completed

Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction

Acute Myocardial Infarction

China
Beijing Mabworks Biotech Co., Ltd.

Completed

A Study of MIL62 in Treatment of CD20 Positive B-cell Lymphomas

CD20-positive B Cell Non-Hodgkin Lymphoma

China
Beijing Northland Biotech. Co., Ltd.

Completed

A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers

Healthy

China
Beijing Northland Biotech. Co., Ltd.

Completed

A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers

Healthy

China
Biocells (Beijing) Biotech Co.,Ltd

Recruiting

BXOS110 Injection in the Treatment of Acute Ischaemic Stroke

Acute Ischemic Stroke

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.

Relapsed or Refractory Multiple Myeloma

China
Toll Biotech Co. Ltd. (Beijing)

Recruiting

A Study of Single and Multiple Oral Doses of TollB-001

Rheumatoid Arthritis

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Clinical Study of MIL62 in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

China
Beijing Mabworks Biotech Co., Ltd.

Recruiting

A Clinical Study of MIL95 in Advanced Malignancies.

Advanced Malignancies

China
Beijing Northland Biotech. Co., Ltd.

Completed

A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11

Chemotherapy-induced Thrombocytopenia

China
Beijing Dongfang Biotech Co., Ltd.

Completed

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09

Diabetes Mellitus, Type 2

China
Beijing Northland Biotech. Co., Ltd.

Completed

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003CLI-II)

Ischemia | Peripheral Vascular Disease | Arterial Occlusive Disease | Ulcers

China
Beijing Dongfang Biotech Co., Ltd.

Unknown

a Study of JY09 in Chinese Healthy Subjects

Healthy
Beijing Mabworks Biotech Co., Ltd.
Betta Pharmaceuticals Co., Ltd.

Completed

mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Beijing Peking University WBL Biotech Co., Ltd.

Completed

Efficacy and Safety Study of Lipid-Lowering Effects of XueZhiKang (XZK) in Patients With Hyperlipidemia

Hyperlipidemia

China, United States
Beijing Kejing Biotechnology Co., Ltd.
Beijing Kejing Biotechnology Corp.

Withdrawn

An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients (CCT-ANK-11)

Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)

China
Angde Biotech Pharmaceutical Co., Ltd.
Beijing Tiantan Hospital

Completed

A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE）

Acute Ischemic Stroke

China
Beijing Tiantan Hospital
Guangzhou Recomgen Biotech Co., Ltd.

Completed

Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ (TRACEⅡ)

Acute Ischemic Stroke

China
Xuanwu Hospital, Beijing
Guangzhou Recomgen Biotech Co., Ltd.

Recruiting

Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window (OPTION)

Acute Ischemic Stroke

China
Angde Biotech Pharmaceutical Co., Ltd.
Beijing Tiantan Hospital

Unknown

A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke.

Acute Ischemic Stroke

China
Cure&Sure Biotech Co., LTD
Beijing Tiantan Hospital

Completed

Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96

Glioma

China
Sinovac Life Sciences Co., Ltd.
Beijing Ditan Hospital

Active, not recruiting

Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 People

COVID-19

China
Shenzhen Xbiome Biotech Co., Ltd.
Beijing Improve-Quality Tech.Co., Ltd.

Recruiting

Safety and Tolerability of FMT Capsules in Healthy Volunteers

Acute-graft-versus-host Disease

China
Beijing Tsinghua Chang Gung Hospital
Beijing DCTY® Biotech Co.,Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma

Recurrent Glioblastoma
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Not yet recruiting

Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination

SARS-CoV-2 | COVID-19 Vaccine

China
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above

COVID-19

China
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Active, not recruiting

Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above

COVID-19

China
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Recruiting

A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years

Herpes Zoster

Australia
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Terminated

Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older

COVID-19

China
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Withdrawn

Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above

COVID-19

China

Clinical Trials Sponsored by Beijing JD Biotech Co. LTD.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations